Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce(TM) Thrombectomy Platform

Stock Information for Surmodics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Surmodics Inc.

Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce(TM) Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil(TM) Drug-Coated Balloon
Surmodics Announces Commercial Release of Pounce(TM) XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.